TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01555749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC172-2021
Description: One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC172-2021
Description: One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: One injection administered subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: One injection administered subcutaneously (s.c., under the skin)
Study: NCT05266690

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Promitor 70
Description: Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Promitor 70
Description: Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Promitor 70
Description: Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Promitor 70
Description: Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber
Study: NCT00910481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-Aortic Balloon Pump
Description: Elective IABP insertion before PCI
Study: NCT00511862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yttrium 90 glass microspheres
Description: 120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe
Study: NCT01886976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-138 cells
Study: NCT03566641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Description: The application of a vacuum across the surface of a wound through a foam dressing cut to fit the wound.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care dressing
Description: The application of a standard care dressing (instead of negative pressure wound therapy) across the surface of wound.
Study: NCT01871298

Intervention type: OTHER
Group type: OTHER
Intervention: Pilot Website Evaluation Component
Description: The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
Study: NCT04495712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: aldosterone blocker

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical in appearance to spironolactone study drug
Study: NCT02349958

Intervention type: DEVICE
Group type: OTHER
Intervention: HIPEC: MMC 30mg @ T0, 10mg @ T45min
Description: MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel

Intervention type: DEVICE
Group type: OTHER
Intervention: HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0
Description: Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min

Intervention type: DEVICE
Group type: OTHER
Intervention: HIPEC: CDDP 75 mg/m2 @T0
Description: Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0

Intervention type: DEVICE
Group type: OTHER
Intervention: HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
Description: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
Study: NCT02281006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans-tympanic injection of a sodium thiosulfate gel
Description: A sodium thiosulfate hyaluronate gel will be prepared by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, DIN 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). On the day before each Cisplatin treatment an otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear.
Study: NCT04544826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: JNJ-77474462 will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: JNJ-77474462 will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: JNJ-77474462 will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to JNJ-77474462 will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to JNJ-77474462 will be administered as SC injection.
Study: NCT02844413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic interval training
Description: In the first group (G1), aerobic interval training (AIT) was undertaken for 5 months (40 professional AIT sessions performed two times per week in 50 minute sessions) and followed a specially developed program. The second control group (G2), did not attend any training sessions but received medical advice on how to maintain physical activity as outlined by JNC hypertension guidelines
Study: NCT01644851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive function training
Description: Computer-based training in executive functions, administered via www.lumosity.com website.
Study: NCT04535141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 MG
Description: It will be a de-identified pill created by investigational drug services at University of North Carolina

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It will be a de-identified pill created by investigational drug services at University of North Carolina
Study: NCT05756595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)
Description: This group will inject once a week. Evaluation of pain score after 30 seconds and 3 hours.
Study: NCT02288325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo taken orally once daily.
Study: NCT04291313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (90µg)
Description: The intervention is a higher dose of vitamin D than what is currently recommended to Danish pregnant women

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 (10µg)
Description: This intervention serves as a control as they get the current recommended vitamin D dose
Study: NCT02996409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HVIGI
Description: High Volume Image-Guided Injection with a saline/lidocain solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LVIGI
Description: Placebo control with injection of a saline/lidocain solution (low volume)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive exercise program
Description: A 12-week during progressive exercise training program consisting of isometric, isotonic and eccentric calf exercises.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Progressive exercise program
Description: A 12-week during progressive exercise training program consisting of isometric, isotonic and eccentric calf exercises.
Study: NCT05496205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iN1011-N17
Description: This study will be conducted in approximately 104 healthy subjects in up to 13 sequential dose cohorts. Thirteen cohorts will consist of up to 8 subjects, including 2 subjects receiving placebo and 6 subjects receiving iN1011-N17.~Each subsequent cohort will continue to be randomized and dosed until maximum exposure is attained or a stopping criterion has been reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iN1011-N17
Description: This study will be conducted in approximately 104 healthy subjects in up to 13 sequential dose cohorts. Thirteen cohorts will consist of up to 8 subjects, including 2 subjects receiving placebo and 6 subjects receiving iN1011-N17.~Each subsequent cohort will continue to be randomized and dosed until maximum exposure is attained or a stopping criterion has been reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iN1011-N17
Description: This study will be conducted in approximately 104 healthy subjects in up to 13 sequential dose cohorts. Thirteen cohorts will consist of up to 8 subjects, including 2 subjects receiving placebo and 6 subjects receiving iN1011-N17.~Each subsequent cohort will continue to be randomized and dosed until maximum exposure is attained or a stopping criterion has been reached.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo for each formulations
Study: NCT01014546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT04587687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study: NCT04493554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Administration of vasopressin (20 IU) intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo intranasally
Study: NCT01204073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-441
Description: TAK-441 will be administered as an oral tablet as follows:~Patients enrolled in the dose escalation cohorts will receive:~* A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed~* Continuous daily dosing on Days 8 through 28 in Cycle 1~* In subsequent cycles, continuous daily dosing over 21 days, repeated continuously~Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle
Study: NCT00337129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: 1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
Study: NCT01738009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction of flow limitation
Study: NCT01382134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin, desmopressin
Description: Aspirin 100mg daily for 3 days Desmopressin 15 microgram subcutaneously once only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, desmopressin
Description: Placebo 1 tab daily for 3 days Desmopressin 15 microgram subcutaneously once only
Study: NCT00003119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study: NCT03977870

Intervention type: OTHER
Intervention: vital status determination
Description: consultation of national registries
Study: NCT01095276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulmozyme (nebulized dornase alpha)
Description: nebulized dornase alpha: 2.5 mg by in-line nebulizer BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline packaged identically to the dornase alpha intervention unit doses and coded for blinding by the company providing the intervention drug (dornase alpha).
Study: NCT00304850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: polyamine-free diet
Description: Polyamine-free diet in the 7 days befor surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: polyamine-free diet
Description: Polyamine-free diet in the 7 days befor surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine or placebo
Description: Peroperative and post operative (48h) ketamine injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine or placebo
Description: Peroperative and post operative (48h) ketamine injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine or placebo
Description: Peroperative and post operative (48h) ketamine injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine or placebo
Description: Peroperative and post operative (48h) ketamine injection
Study: NCT01479075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intransal insulin
Description: 4x 40mU intranasal insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intransal insulin
Description: 4x 40mU intranasal insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham stimulation
Study: NCT00003119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study: NCT03885661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl 1000 MG [Vascepa]
Description: Icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA). The empirical formula of icosapent ethyl is C22H34O2 and the molecular weight is 330.51. The chemical name for icosapent ethyl is ethyl all-cis-5,8,11,14,17-icosapentaenoate.
Study: NCT02282540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iodixanol to the Eustachian tube
Description: Application of iodixanol to the middle ear for imaging of the ET.
Study: NCT02822014

Intervention type: OTHER
Group type: OTHER
Intervention: FDG-PET/CT
Description: We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients.
Study: NCT00003119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01594580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antimicrobial impregnated scrubs
Description: Scrubs are impregnated with an antimicrobial product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-impregnated scrubs
Study: NCT00958685

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ginger
Description: Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
Study: NCT02192216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT02177773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo Gallium Ga 68-DOTA-TOC PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-Edotreotide
Description: Given Intravenously (IV) before imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo gallium Ga 68-DOTA-TOC PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo gallium Ga 68-DOTA-TOC PET in combination with CT or MRI
Study: NCT01818414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 mcg of buccal misoprostol, 3 hours prior to planned D\&E

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: 4 mg of buccal folic acid, 3 hours prior to planned D\&E
Study: NCT02043093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sources of Strength
Description: Sources of Strength (http://www.sourcesofstrength.com/) has three phases:~1. Introduction to school and community partners. Staff advisors for the program are identified and trained.~2. A standard process is used for nominating student peer leaders, who are trained through a 4-hour interactive workshop. A major focus is on increasing knowledge of 'sources of strength' and skills for increasing use of those resources for themselves and other students.~3. Peer Leaders plan and conduct messaging with Adult Advisor mentoring. A school-wide messaging phase involves presentations; media campaigns through posters, public service announcements, videos.
Study: NCT04215653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium
Description: administered orally once every 30-60 minutes before breakfast for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: administered orally once every 30-60 minutes before breakfast for 4 weeks
Study: NCT04544826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to JNJ-77474462 will be administered as SC injection.
Study: NCT01476046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1995057 single dose
Description: Single intravenous dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous dose
Study: NCT01281930

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full packing into abscess cavity
Description: After incision and drainage plain 1/4-1/2 inch gauze packing material is placed into the cavity to fill it

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wick placement into abscess cavity
Description: After incision and drainage of the abscess a piece of plain gauze 1/4-1 inch packing material that is as wide as can be easily passed through the opening is placed into the cavity spanning one diameter of the cavity
Study: NCT03524404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 Week Intervention
Description: Weekly interactive webinars based on the DPP curriculum at senior center.
Study: NCT02605057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 80185 gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovobet(r) Ointment
Study: NCT02187757

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study Dietary Supplement (Prelipid 500 mg capsules)
Description: Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with lifestyle modification.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04215653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Placebo
Description: administered orally once every 30-60 minutes before breakfast for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anaprazole Sodium Placebo
Description: administered orally once every 30-60 minutes before breakfast for 4 weeks
Study: NCT01839734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Lubiprostone 24 mcg by mouth (PO) once-daily
Study: NCT03243526

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fluid therapy
Description: fluid resuscitation guided by CVP or PPV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid therapy
Description: fluid resuscitation guided by CVP or PPV
Study: NCT00401570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volociximab
Description: Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volociximab
Description: Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment
Study: NCT00783536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept + Methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARDS
Study: NCT04082026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Adolescent Skills for Emotions EASE)
Description: EASE is conducted in 7 weekly group sessions with adolescents. EASE sessions help adolescents:~* Identify their feelings and body reactions~* Practice breathing exercises~* Get active: Make a plan to positively change their actions~* Manage their problems

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Early Adolescent Skills for Emotions EASE)
Description: EASE is conducted in 7 weekly group sessions with adolescents. EASE sessions help adolescents:~* Identify their feelings and body reactions~* Practice breathing exercises~* Get active: Make a plan to positively change their actions~* Manage their problems
Study: NCT04463407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational talk about physical activity and nutritional recommendations before a critical period of fat gain in university students
Description: An intervention was performed emulating a traditional nutritional session from a primary healthcare center (public health system). Traditionally, this session lasts around 20 minutes and includes a body composition measurement, nutritional assessment, and a brief educational talk about healthy eating. Just the intervention group received a series of healthy recommendations specially focused on the National Holiday.